In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Consumer Health Product Recalls For May 4-25, 2016

This article was originally published in The Tan Sheet

Executive Summary

Recalls reported by FDA for OTC drugs, nutritionals and personal care products.

You may also be interested in...



Keystone Labs Court-Ordered To Halt OTC Drug Manufacturing; Cosmetics Not Affected, It Says

Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.

Keystone Labs Keeps OTC Drugs In Plans After Court Orders Manufacturing Halt

Keystone Labs agrees to cease manufacturing OTC drugs after repeat GMP violations following a 2013 FDA warning letter, including failure to investigate sources of contamination. Firm says it informed FDA it would outsource OTC product manufacturing and continue making hair and skin care cosmetic formulas.

Keystone Labs Keeps OTC Drugs In Plans After Court Orders Manufacturing Halt

Keystone Labs agrees to cease manufacturing OTC drugs after repeat GMP violations following a 2013 FDA warning letter, including failure to investigate sources of contamination. Firm says it informed FDA it would outsource OTC product manufacturing and continue making hair and skin care cosmetic formulas.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel